1
|
Shehata M, Al Hosani I, Singh Y, Alali A, Khan S, Al Zaabi M, Khadam O, Alahmad M, Syed R, Al Tiniji K, Aljanahi A, Al Akrad E. Factors Associated With Delayed Gastric Emptying in Symptomatic Diabetic and Non-diabetic Patients: A Retrospective Observational Study. Cureus 2024; 16:e58038. [PMID: 38606023 PMCID: PMC11008549 DOI: 10.7759/cureus.58038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/11/2024] [Indexed: 04/13/2024] Open
Abstract
Background Gastroparesis, characterized by delayed gastric emptying without mechanical obstruction, is a significant complication, especially in diabetic individuals. It manifests through symptoms such as abdominal bloating, feelings of fullness, and pain. This study investigates the prevalence of gastroparesis among non-diabetic and diabetic patients, exploring associations with demographic data, hemoglobin A1C (HbA1C) levels, and symptoms. Methodology This retrospective, observational, cohort study included patients with gastroparesis symptoms who underwent a nuclear gastric emptying study from January 2021 to April 2023. The study analyzed demographic data, symptoms, and HbA1c levels to identify correlations with delayed gastric emptying. Results Of 157 patients, 34.4% exhibited delayed gastric emptying. Diabetic patients comprised 29.3% of the sample, with a notable disease duration of over 10 years in 77.3% of cases. Symptoms such as nausea, vomiting, epigastric pain, and early satiety were prevalent, with significant associations between delayed emptying and female gender, higher HbA1c, and vomiting. Conclusions Delayed gastric emptying is significantly associated with female gender, elevated HbA1c levels, and when vomiting is the presenting symptom. Highlighting the importance of awareness among healthcare providers and the community, the findings encourage collaborative efforts for further gastroparesis research to better understand the predictive factors and mechanisms.
Collapse
Affiliation(s)
- Mostafa Shehata
- Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, ARE
| | | | - Yashbir Singh
- Department of Radiology, Mayo Clinic, Rochester, USA
| | - Ameirah Alali
- Gastroenterology and Hepatology, Sheikh Shakhbout Medical City, Abu Dhabi, ARE
| | - Shaima Khan
- Gastroenterology and Hepatology, Sheikh Shakhbout Medical City, Abu Dhabi, ARE
| | - Mohamed Al Zaabi
- Gastroenterology and Hepatology, Sheikh Shakhbout Medical City, Abu Dhabi, ARE
| | - Omar Khadam
- Internal Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, ARE
| | - Maryam Alahmad
- Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, ARE
| | - Rizwan Syed
- Radiology, Sheikh Shakhbout Medical City, Abu Dhabi, ARE
| | | | - Abdulla Aljanahi
- Internal Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, ARE
| | - Eyad Al Akrad
- Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, ARE
| |
Collapse
|
2
|
Patel A, Arora GS, Roknsharifi M, Javed H, Kaur P. Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety. Cureus 2023; 15:e48303. [PMID: 38058346 PMCID: PMC10696281 DOI: 10.7759/cureus.48303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/04/2023] [Indexed: 12/08/2023] Open
Abstract
This meta-analysis aimed to evaluate the efficacy and safety of relamorelin, a synthetic ghrelin receptor agonist, for the treatment of gastroparesis and diabetic gastroparesis. A total of 1,033 participants from five randomized controlled trials were included. The primary outcome was the mean change in gastric emptying time from baseline. Relamorelin demonstrated a statistically significant improvement in gastric emptying time with a mean difference of -11.40 minutes compared to the placebo group. Furthermore, a significant improvement was observed specifically in diabetic gastroparesis patients, with a mean difference of -8.43 minutes. However, adverse effects, such as headaches, dizziness, and gastrointestinal symptoms, were more prevalent in the relamorelin group. Despite these adverse effects, the study concludes that relamorelin offers a promising avenue for gastroparesis treatment, especially given the limited existing therapeutic options. This comprehensive meta-analysis synthesizes existing evidence to inform clinical practice and guides future research in this domain.
Collapse
Affiliation(s)
- Akash Patel
- Internal Medicine, Eisenhower Health, Rancho Mirage, USA
| | - Gagandeep Singh Arora
- Hepatobiliary Pancreatic Surgery and Liver Transplant, BLK-Max Super Speciality Hospital, New Delhi, IND
- Internal Medicine, University of California, Riverside, San Bernardino, USA
| | - Mona Roknsharifi
- Internal Medicine, University of California, Riverside, San Bernardino, USA
| | - Hamna Javed
- Internal Medicine, Saint Agnes Medical Center, Fresno, USA
| | - Parneet Kaur
- Emergency, Civil Hospital Mukerian, Mukerian, IND
- Internal Medicine, Suburban Community Hospital, Philadelphia, USA
| |
Collapse
|